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Abstract
Background:  Carcinoid  of  the  small  intestine,  is  a  well-differentiated  neuroendocrine  tumour
that rarely  presents  with  clinical  signs.  This  tumour  can  be  associated  with  other  conditions,
such as  inﬂammatory  bowel  disease,  presenting  a  wide  range  of  symptoms.  In  some  cases  they
have an  aggressive  and  highly  symptomatic  behaviour;  thus,  clinical  suspicion  must  be  high  to
make an  early  diagnosis.
Clinical  case:  A  60  year-old  male  patient  with  Crohn’s  disease  and  gastrointestinal  symptoms
attributed  to  this  disease  within  the  last  year.  He  presented  with  intestinal  obstruction  ini-
tially treated  with  conservative  management  with  no  improvement.  Exploratory  laparotomy
was performed  ﬁnding  a  mesenteric  tumour  that  caused  the  bowel  obstruction.
Bowel resection  with  primary  anastomosis  was  performed.  The  pathology  report  showed  an
intestinal  carcinoid  tumour  with  lymph  node  metastases.  The  patient  recovered  well,  and  was
discharged  without  complications  to  continue  medical  treatment  and  follow-up  by  the  Oncology
department.
Conclusion:  In  almost  42%  of  the  cases,  the  most  common  site  of  carcinoid  tumours  is  the  small
intestine,  and  of  these,  41%  are  presented  as  locoregional  disease.  Patients  with  Crohn’s  disease
present a  higher  incidence.  In  these  cases,  the  most  common  presentation  is  an  acute  intestinal
obstruction  (90%).  Surgery  is  usually  curative,  and  follow  up  is  important  as  the  symptoms  of
Crohn’s disease  can  hide  any  recurrence.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
 Please cite this article as: Mussan-Chelminsky G, Vidal-González P, Nún˜ez-García E, Valencia-García LC, Márquez-Ugalde MA. Tumor
arcinoide intestinal: reporte de un caso. Cir Cir. 2015;83:438--441.
∗ Corresponding author at: Centro Médico ABC, Campus Santa Fe, Av. Carlos Graef Fernández #154, Consultorios 108-109, Col. Tlaxcala
anta Fe, Cuajimalpa, 05300 México, D.F., Mexico. Tel.: +52 1103 1600; fax: +52 1103 1681.
E-mail address: gmussan@prodigy.net.mx (G. Mussan-Chelminsky).
444-0507/© 2015 Academia Mexicana de Cirugía A.C. Published by Masson Doyma México S.A. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Intestinal  carcinoid  tumourr  439
PALABRAS  CLAVE
Tumor  carcinoide;
Oclusión  intestinal;
Neoplasia
neuroendocrina
Tumor  carcinoide  intestinal:  reporte  de  un  caso
Resumen
Antecedentes:  El  carcinoide  intestinal  es  una  neoplasia  neuroendocrina  del  intestino  delgado
que en  pocas  ocasiones  se  presenta  con  manifestaciones  clínicas.  Estos  tumores  pueden  estar
asociados  a  otras  patologías,  como  enfermedad  inﬂamatoria  intestinal,  y  tienen  un  rango  amplio
de sintomatología,  aunque  la  mayoría  crecen  lentamente  y  producen  síntomas  poco  especíﬁcos.
En algunos  casos  tienen  un  comportamiento  agresivo  y  altamente  sintomático,  por  lo  que  la
sospecha  clínica  debe  ser  alta  para  realizar  un  diagnóstico  temprano.
Caso clínico: Masculino  de  60  an˜os  con  antecedente  de  enfermedad  de  Crohn  y  síntomas  gas-
trointestinales  de  un  an˜o  de  evolución,  atribuidos  a  dicha  enfermedad.  Presentó  cuadro
de oclusión  intestinal  sin  mejoría  con  manejo  conservador.  Se  realizó  laparotomía  explo-
radora, encontrando  tumoración  del  mesenterio,  la  cual  condicionaba  una  obstrucción  intestinal
mecánica.
Se realizó  resección  intestinal  con  anastomosis  primaria.  El  reporte  histopatológico  evidenció
un tumor  carcinoide  intestinal  con  metástasis  ganglionares.  Evolucionó  adecuadamente  y  fue
dado de  alta  para  continuar  tratamiento  médico  y  seguimiento  por  oncología.
Conclusiones:  El  sitio  más  común  de  presentación  de  los  tumores  carcinoides  es  el  intestino
delgado hasta  en  un  42%  de  los  casos;  de  estos,  el  41%  se  presentan  como  patología  locorre-
gional. Existe  una  mayor  incidencia  en  pacientes  con  enfermedad  de  Crohn  y  en  estos  casos,  la
presentación  más  común  es  un  cuadro  agudo  de  obstrucción  intestinal  (90%).  La  cirugía  suele
ser curativa  y  el  seguimiento  es  importante,  ya  que  los  síntomas  de  la  enfermedad  de  Crohn
pueden ocultar  alguna  recidiva.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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(Fig.  1),  which  was  causing  obstruction  and  had  involved
approximately  60  cm  of  the  loops  of  the  small  intestine,
including  the  ileocaecal  valve  with  inter-loop  adherences,Background
Carcinoid  of  the  intestine  is  a  neuroendocrine  neoplasia  of
the  small  intestine  which  usually  presents  insidiously,  due
to  its  slow  growth  and  its  minimally  aggressive  behaviour.
It  is  associated  with  other  pathologies,  such  as  non-speciﬁc
chronic  ulcerative  colitis  and  Crohn’s  disease.  Symptoms  can
be  non-speciﬁc  and  can  be  confused  with  the  abovemen-
tioned  diseases  or  functional  gastrointestinal  disorders.1
Clinical case
A  60-year  old  male  patient  with  a  diagnosis  of  Crohn’s  dis-
ease  of  10  years  evolution,  treated  with  mesalazine.
A  year  prior  to  admission,  the  patient  started  to  expe-
rience  non-speciﬁc,  generalised,  abdominal  pain  associated
with  intermittent  episodes  of  diarrhoea  with  no  mucous  or
blood,  which  was  managed  medically;  it  partially  improved
temporarily.  He  attended  the  emergency  department  due
to  increased  abdominal  pain,  and  nausea  without  vomi-
ting.  On  physical  examination  his  abdomen  was  distended,
there  was  increased  peristalsis  in  the  lower  quadrants,  gen-
eralised  pain  on  superﬁcial  and  deep  palpation,  tympanic
on  percussion,  with  no  signs  of  peritoneal  irritation.  The
initial  results  of  the  laboratory  tests  showed  no  changes;
abdominal  tomography  was  requested,  which  showed  thick-
ening  of  the  intestinal  wall  with  signs  of  intestinal  occlusion,
inﬂammatory  changes  in  the  mesenteric  fat,  mesenteric
adenopathies  and  free  ﬂuid  in  the  pelvic  cavity.
F
tIt  was  decided  to  opt  for  conservative  management
ith  naso-gastric  tube.  However,  24  h  after  the  patient
as  admitted,  his  pain  increased  and  he  presented  leuko-
ytosis  of  11,800/mm3, with  3%  bands,  and  therefore  an
xploratory  laparotomy  was  performed.  A  ﬁbrotic  tumour
as  found  in  the  mesentery  20  cm  from  the  ileocaecal  valveigure  1  The  arrow  shows  mesenteric  ﬁbrosis  secondary  to
he desmoplastic  reaction  caused  by  the  intestinal  carcinoid.
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Figure  2  Group  of  cells  corresponding  to  a  grade  1  neu-
roendocrine  neoplasia  (carcinoid  tumour)  which  is  inﬁltrating
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che lamina  propria,  muscularis  mucosae,  submucosa,  muscularis
ropria  and  serosa.
nd  4  extracapsular  punctiform  lesions  of  hard  consistency,
 mm  in  diameter  in  the  anterior  surface  of  the  liver.
A  60  cm  resection  was  made  of  the  terminal  and
lind  ileum,  with  ileo-ascending  anastomosis,  latero-lateral
echanics,  as  well  as  a  biopsy  of  one  of  the  hepatic  lesions.
The  patient  recovered  satisfactorily,  and  was  discharged
n  the  seventh  postoperative  day  with  adequate  oral  toler-
nce  and  gastrointestinal  function.
The  pathology  report  showed  a  grade  one  neuroendocrine
eoplasia,  with  negative  surgical  borders.  The  tumour  was
arcinoid,  its  longest  diameter  was  2.5  cm  and  the  shortest
as  2  cm,  and  it  was  inﬁltrating  the  serosa,  as  well  as  4  out
f  15  lymph  nodes  with  metastases  (Figs.  2  and  3).
iscussionarcinoid  of  the  intestine  is  the  most  common  malignant
umour  of  the  distal  small  intestine.  In  up  to  42%  of  cases
t  presents  in  the  small  intestine,  and  41%  of  these  cases
igure  3  Diffuse  positive  for  chromogranin  A  in  neoplastic
ells.
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resent  as  locoregional  disease.  Its  incidence  is  increasing,
t  0.67/100,000  inhabitants  with  carcinoid  tumours  of  the
ejunum  and  ileum;  it  is  similar  for  both  sexes,  and  the
verage  age  of  presentation  is  66.  Although  its  prevalence
s  relatively  high,  the  presence  of  symptoms  or  carcinoid
yndrome  is  very  rare.1 When  it  presents  clinically,  12%  of
atients  have  distant  metastases,  whereas  carcinoid  syn-
rome  only  occurs  in  one  out  of  300,000  patients  with  this
umour.2
Carcinoid  tumours  form  part  of  the  neuroendocrine  neo-
lasias  that  derive  from  the  enterochromafﬁn  cells  of  the
ntestinal  crypts,  which  share  a  common  source  in  the
ctoderm;  these  cells  synthesise  serotonin  from  trypto-
han  absorbed  in  the  gastrointestinal  tract.3 Two  enzymes
re  involved  in  serotonin  synthesis:  tryptophan  hydrox-
lase,  which  catalyses  the  conversion  of  tryptophan  in
-hydroxyindolacetic  acid  (5-HIIA),  and  monoamine  oxidase:
-HIIA  is  metabolised  by  the  kidney,  and  its  levels  increase  in
rine  in  the  presence  of  a  carcinoid  tumour,  which  supports
he  diagnosis  of  this  disease.3,4
Clinical  presentation  is  due  to  the  pathophysiological
echanisms  involved,  and  symptoms  can  be  secondary  to
he  tumour  or  to  carcinoid  syndrome;  manifestations  are
cute,  and  chronic,  depending  on  the  evolution  time  of  the
umour.  Intestinal  obstruction  is  the  most  common  acute
resentation  (90%  of  cases)  and  occurs  secondary  to  the
esmoplastic  reaction  that  this  generates,  in  both  the  intes-
ine  and  the  mesentery.  This  reaction  can  cause  acute
esenteric  ischaemia  in  30%  of  cases.  Another  acute  intesti-
al  manifestation  is  bleeding  from  the  digestive  tract,  which
s  usually  not  abundant,  and  due  to  its  location,  can  be
ifﬁcult  to  identify.3,4
Chronic  intestinal  manifestations  usually  present  with  a
istory  of  pain  over  several  months  or  years,  and  are  usually
iagnosed  mistakenly  as  malabsorption  syndrome  or  irritable
owel  syndrome,  due  to  the  association  with  changes  in
owel  habits.  Chronic  presentation  can  even  reﬂect  an  asso-
iated  condition  which  is  related  to  carcinoid  tumours,  such
s  Crohn’s  disease.4
Patients  with  Crohn’s  disease  present  more  frequently
ith  gastrointestinal  tumours  compared  with  the  general
opulation.  The  malignant  strains  associated  with  this
isease  are  adenocarcinoma,  lymphoma  and  epidermoid
arcinoma.5
There  is  evidence  of  the  association  between  patients
ith  Crohn’s  disease  and  intestinal  carcinoid.  West  et  al.6
resented  a  series  of  cases  where  they  concluded  that  car-
inoid  tumours  are  15  times  more  common  in  patients  with
rohn’s  disease,  a  3.6%  incidence  compared  with  0.25%  in
he  control  group,  in  addition  to  the  increased  risk  of  pre-
enting  carcinoid  tumours,  the  symptoms  from  this  tumour
an  be  falsely  attributed  to  Crohn’s  disease,  and  this  is  why
here  are  delays  in  diagnosis.7
The  secondary  presentation  of  carcinoid  syndrome  only
ccurs  when  there  are  liver  metastases,  as  these  secrete
erotonin,  as  well  as  other  derivatives  of  tryptophan
etabolism.  The  most  common  manifestations  of  this  syn-
rome  include:  facial  reddening,  diarrhoea,  abdominal  pain,
elangiectasias,  oedema  and  signs  of  cardiac  dysfunction.4
Abdominal  tomography  is  the  study  of  choice  for  diag-
osing  carcinoid  tumours  of  the  intestine.  It  is  used  to
etect  tumours,  metastasis,  and  to  identify  the  anatomy.
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Abdominal  ultrasound  is  the  most  sensitive  test  for  liver
metastases  of  less  than  1  cm.8 In  terms  of  functional  tests;
radionuclide  scanning  with 111In-octreotide  has  83%  diag-
nostic  sensitivity  and  100%  positive  predictive  value.  Useful
markers  in  diagnosis  are  chromogranin  A  and  5-HIIA,  which
has  88%  speciﬁcity  and  35%  sensitivity;  however,  these  can
be  high  in  the  presence  of  other  types  of  neuroendocrine
tumours.3
The  principal  treatment  objective  is  to  increase  sur-
vival,  and  to  control  symptoms  and  improve  quality  of  life.
This  can  be  achieved  by  wide  surgical  resection,  includ-
ing  the  mesentery  and  lymph  nodes.  Revision  of  the  entire
intestine  is  essential,  as  there  are  other  carcinoid  tumours
of  the  intestine  in  25%  of  cases.  If  full  resection  is  not
possible  due  to  retroperitoneal  spread  or  spread  to  the
large  vessels,  cytoreductive  surgery  should  be  performed,
with  a  view  to  reducing  or  normalising  5-HIIA  levels,  to
reduce  systemic  symptoms  and  prevent  local  complications.
There  are  several  options  in  cytoreductive  therapy,  such
as  ablation  with  radiofrequency,  cryotherapy  and  surgical
metastasectomy.4,9 A  survival  of  71%  at  5  years  and  complete
resolution  of  the  symptoms  of  carcinoid  syndrome  between
4  and  120  months  in  86%  of  cases  was  reported  in  a  meta
analysis  where  partial  cytoreductive  hepatectomy  was  per-
formed.  In  cases  where  the  metastases  are  unresectable,
arterial  embolism  can  be  performed  to  reduce  the  tumour
and  the  symptoms  of  carcinoid  syndrome.9
The  response  to  chemotherapy  is  variable,  it  rarely
exceeds  30%.  Commonly  used  drugs  are  5-ﬂuorouracil  and
streptozocin,  although  results  are  generally  not  favourable
and  they  are  only  used  palliatively.  Radiotherapy  does  not
play  a  therapeutic  role  and  its  use  is  limited  to  painful
bone  metastases  or  metastases  of  the  central  nervous
system.4,9
The  prognosis  and  follow-up  of  patients  with  intestinal
carcinoid  depends  on  their  clinical  condition  at  the  time  of
diagnosis,  and  the  therapy  that  they  have  received.  Mon-
itoring  with  serum  markers  such  as  chromogranin  A  and
5-HIAA  should  be  carried  out  routinely  every  6  months,  and
for  the  ﬁrst  3  years,  and  subsequently  annually.  Abdomi-
nal  tomography  is  recommended  during  the  ﬁrst  3  years,
and  subsequently  the  need  for  this  test  should  be  evaluated
with  laboratory  ﬁndings  and  clinical  symptoms.  The  decision
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o  suspend  monitoring  after  the  ﬁfth  year  post  treatment
epends  on  the  clinical  evolution  during  this  time.10
onclusions
arcinoid  tumours  are  rare  and  have  a  wide  range  of  symp-
oms;  the  majority  are  slow-growing  and  have  non-speciﬁc
ymptoms.  Therefore  early  suspected  diagnosis  and  appro-
riate  treatment  will  be  of  greatest  beneﬁt  to  patients.
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